Physician profile
Ester Yang
NPI 1154015907
$848.10
in general payments reported to CMS, 2019-2025
15 companies · $573 in 2025
The $573 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $275 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $200.00 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $104.49 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.83 | 2024-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $80.55 | 2024-2025 | Veozah |
| Abbvie INC. | $66.32 | 2025 | |
| Lilly USA, LLC | $62.90 | 2025 | Jardiance, Kisunla, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $48.49 | 2024 | Farxiga |
| Exact Sciences Corporation | $46.18 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $31.07 | 2025 | Capvaxive |
| Glaxosmithkline, LLC. | $25.18 | 2025 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $24.67 | 2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.59 | 2024 | Jardiance |
| Abbott Laboratories | $19.65 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $18.48 | 2024 | Evenity, Prolia |
| Phathom Pharmaceuticals, INC. | $16.70 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ester Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.